Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CTSV | O60911 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550116 | 0.85 | ALDH1A1 (0.59) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL7422406 | 0.84 | KMT2A (0.65) | ALDH1A1TDP1CYP3A4ALOX15KMT2A | |
| SCHEMBL19971993 | 0.84 | ALDH1A1 (0.52) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL260006 | 0.82 | ALDH1A1 (0.70) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL27278834 | 0.82 | CES2 (0.56) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL11810168 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| Hydrochloric Acid SCHEMBL10694666 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL7824186 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| Hydrochloric Acid SCHEMBL10694658 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL11351093 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4ALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10546303-B2 | Optically visible carbon nanotube with nanocrystals decoration as unique ID | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2020-01-28 | — | — | US | claimed |
| US-20180276682-A1 | Optically Visible Carbon Nanotube with Nanocrystals Decoration as Unique ID | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2018-09-27 | — | — | US | claimed |
| US-20150290344-A1 | BIODEGRADABLE POLYESTER- AND POLY(ESTER AMIDE) BASED X-RAY IMAGING AGENTS | CLEMSON UNIVERSITY RESEARCH FOUNDATION | 2015-10-15 | — | — | US | claimed |
| CN-1112548-A | Polyiodinated compounds, process for preparing them and diagnostic compositions | GUERBET SA (FR) | 1995-11-29 | — | — | CN | claimed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4717316-A2 | ANTI-EGFR ANTIBODY-DRUG CONJUGATES | AbbVie Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4663628-A1 | NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Samjin Pharmaceutical Co., Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20040122038-A1 | NPY-5 antagonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| CN-1112548-A | Polyiodinated compounds, process for preparing them and diagnostic compositions | GUERBET SA (FR) | 1995-11-29 | — | — | CN | disclosed |
| EP-0468683-B1 | Fungicidal acylamidobenzamides | ZENECA LTD (GB) | 1995-06-14 | — | — | EP | disclosed |
| CN-1058392-A | Mycocide | ICI PLC (GB) | 1992-02-05 | — | — | CN | disclosed |
| EP-0468683-A1 | Fungicidal acylamidobenzamides | ZENECA LIMITED (GB) | 1992-01-29 | — | — | EP | disclosed |
| EP-0098098-B1 | ACRIDINECARBOXAMIDE COMPOUNDS | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1989-02-08 | — | — | EP | disclosed |
| US-4590277-A | BACTERICIDES, ANTITUMOR AGENTS | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1986-05-20 | — | — | US | disclosed |
| EP-0098098-A2 | Acridinecarboxamide compounds | DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290344-A1 | BIODEGRADABLE POLYESTER- AND POLY(ESTER AMIDE) BASED X-RAY IMAGING AGENTS | PUF60, ARG1, PAM | ALDH1A1 3356/4885TDP1 1122/4885CYP3A4 2600/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | ALDH1A1 1891/4885TDP1 4598/4885CYP3A4 3894/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | ALDH1A1 951/4885TDP1 3222/4885CYP3A4 3236/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | ALDH1A1 2347/4885TDP1 4095/4885CYP3A4 3014/4885 |
| US-20250263491-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | ALDH1A1 1891/4885TDP1 4598/4885CYP3A4 3894/4885 |
| US-20040122038-A1 | NPY-5 antagonists | NPY5R, NPY1R, NPY2R | ALDH1A1 2832/4885TDP1 2467/4885CYP3A4 3008/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | ALDH1A1 2826/4885TDP1 3899/4885CYP3A4 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.